drugset / Trial / NCT06926478
Subconjunctival Humira for Boston Keratoprosthesis
NaSingle-groupOpen-labelTreatment
Summary
This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-06-01
- Completion
- 2028-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 4 mg | — |